Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure

dc.contributor.authorVogler, Sabine
dc.contributor.authorSchneider, Peter
dc.contributor.authorZuba, Martin
dc.contributor.authorBusse, Reinhard
dc.contributor.authorPanteli, Dimitra
dc.date.accessioned2021-07-09T13:06:40Z
dc.date.available2021-07-09T13:06:40Z
dc.date.issued2021-06-25
dc.date.updated2021-07-09T08:17:54Z
dc.description.abstractIntroduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs about different policy measures employed by European countries to design the biologicals market and explores potential savings from the increased use of biosimilar medicines in Germany. Methods: Policy measures that target the price and uptake of biosimilar medicines were identified based on a prefilled questionnaire survey with public authorities in 16 European countries, who were the members of the Pharmaceutical Pricing and Reimbursement Information network (July 2020). Potential savings that could have been generated in Germany if different measures identified in the surveyed countries had been implemented were calculated for six publicly funded biological molecules. Price data of the Pharma Price Information service and German consumption data for 2018 were used for the calculation of five scenarios. Results: Several countries use a price link policy, setting the biosimilar price as a percentage of the price of the reference biological. Also lowering the price of the reference biological upon market entry of a biosimilar is less frequently used. While tendering of biosimilar medicines in the inpatient setting is the norm, it is rarely employed for biosimilars in outpatient use. Reference price systems and INN prescribing of medicines are the commonly used policy measures in the off-patent market, but some countries define exemptions for biologicals. Substituting biosimilars at the pharmacy level is rather an exception. Potential savings in Germany ranged from 5% (simple price link) to 55% (prices at the level of other countries) for the six studied molecules. Conclusion: Despite some differences, there are discernible tendencies across European countries with regard to their applications of certain policy measures targeting the price and uptake of biosimilar medicines. The potential for savings of some of these policies was clearly demonstrated. Monitoring and evaluation of these rather recent measures is key for obtaining a more comprehensive picture of their impact.en
dc.description.sponsorshipDFG, 414044773, Open Access Publizieren 2021 - 2022 / Technische Universität Berlinde
dc.identifier.eissn1663-9812
dc.identifier.urihttps://depositonce.tu-berlin.de/handle/11303/13390
dc.identifier.urihttp://dx.doi.org/10.14279/depositonce-12174
dc.language.isoenen
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subject.ddc610 Medizin und Gesundheitde
dc.subject.otherbiologicalen
dc.subject.otherbiosimilaren
dc.subject.othersavingsen
dc.subject.othersubstitutionen
dc.subject.othercross-country comparisonen
dc.subject.otherpolicy measureen
dc.titlePolicies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditureen
dc.typeArticleen
dc.type.versionpublishedVersionen
dcterms.bibliographicCitation.articlenumber625296en
dcterms.bibliographicCitation.doi10.3389/fphar.2021.625296en
dcterms.bibliographicCitation.journaltitleFrontiers in Pharmacologyen
dcterms.bibliographicCitation.originalpublishernameFrontiersen
dcterms.bibliographicCitation.originalpublisherplaceLausanneen
dcterms.bibliographicCitation.volume12en
tub.accessrights.dnbfreeen
tub.affiliationFak. 7 Wirtschaft und Management::Inst. Technologie und Management (ITM)::FG Management im Gesundheitswesende
tub.affiliation.facultyFak. 7 Wirtschaft und Managementde
tub.affiliation.groupFG Management im Gesundheitswesende
tub.affiliation.instituteInst. Technologie und Management (ITM)de
tub.publisher.universityorinstitutionTechnische Universität Berlinen

Files

Original bundle
Now showing 1 - 3 of 3
Loading…
Thumbnail Image
Name:
fphar-12-625296.pdf
Size:
713.31 KB
Format:
Adobe Portable Document Format
No Thumbnail Available
Name:
DataSheet2.docx
Size:
18.1 KB
Format:
Microsoft Word XML
No Thumbnail Available
Name:
DataSheet1.docx
Size:
15.76 KB
Format:
Microsoft Word XML
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.9 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections